Results 11 to 20 of about 52,468 (237)

Potential Early Risk Biomarkers for Reduced Forced Expiratory Volume in Children Post‐Hematopoietic Cell Transplantation

Pediatric Blood &Cancer, EarlyView.
ABSTRACT We sought to identify potential early risk biomarkers for lung disease in children post‐allogeneic HCT. Patients with pulmonary function tests 3 months post‐transplant and plasma samples between days 7 and 14 post‐HCT were included. Six of 27 subjects enrolled had reduced forced expiratory volume 1 (FEV1) z scores.
Isabella S. Small, Pi Chun Cheng, April L. Rahrig, Courtney M. Rowan   +3 more
wiley   +1 more source

\u3cem\u3eMason v. The Ship Blaireau\u3c/em\u3e: Salvage, Slaves, and the Law of Nations [PDF]

, 2013
In March 1803, French ship Le Blaireau ran into Spanish ship of war St. Julien in the middle of the Atlantic Ocean, severely damaging the Blaireau such that her captain and crew abandoned ship and boarded the St.
Burnworth, Kristin
core   +1 more source

Structural insights into lacto‐N‐biose I recognition by a family 32 carbohydrate‐binding module from Bifidobacterium bifidum

FEBS Letters, EarlyView.
Bifidobacterium bifidum establishes symbiosis with infants by metabolizing lacto‐N‐biose I (LNB) from human milk oligosaccharides (HMOs). The extracellular multidomain enzyme LnbB drives this process, releasing LNB via its catalytic glycoside hydrolase family 20 (GH20) lacto‐N‐biosidase domain.
Xinzhe Zhang, Naoki Sunagawa, Toma Kashima, Kiyohiko Igarashi, Akimasa Miyanaga, Shinya Fushinobu   +5 more
wiley   +1 more source

Structural biology of ferritin nanocages

FEBS Letters, EarlyView.
Ferritin is a conserved iron‐storage protein that sequesters iron as a ferric mineral core within a nanocage, protecting cells from oxidative damage and maintaining iron homeostasis. This review discusses ferritin biology, structure, and function, and highlights recent cryo‐EM studies revealing mechanisms of ferritinophagy, cellular iron uptake, and ...
Eloise Mastrangelo, Flavio Di Pisa
wiley   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

Posebna naknada prema Konvenciji o spašavanju iz 1989. : [prikaz presude]

Uporedno pomorsko pravo, 1996
Posebna naknada na koju spašavatelj ima pravo pod uvjetima iz čl.14. Konvencije o spašavanju iz 1989. [dalje: Konvencija] utvrđuje se u visini troškova kojima je spašavatelj bio izložen tijekom operacije spašavanja. Prema čl.14. st.3.
Dorotea Ćorić
doaj  

Doppler ultrasound surveillance of recently formed haemodialysis arteriovenous fistula: the SONAR observational cohort study

Health Technology Assessment
Background Arteriovenous fistulas are considered the best option for haemodialysis provision, but as many as 30% fail to mature or suffer early failure. Objective To assess the feasibility of performing a randomised controlled trial that examines whether,
James Richards, Dominic Summers, Anna Sidders, Elisa Allen, Mohammed Ayaz Hossain, Subhankar Paul, Matthew Slater, Matthew Bartlett, Regin Lagaac, Emma Laing, Valerie Hopkins, Chloe Fitzpatrick-Creamer, Cara Hudson, Joseph Parsons, Samuel Turner, Andrew Tambyraja, Subash Somalanka, James Hunter, Sam Dutta, Neil Hoye, Sarah Lawman, Tracey Salter, Mohammed Farid Aslam, Atul Bagul, Rajesh Sivaprakasam, George E Smith, Helen L Thomas, Zia Moinuddin, Simon R Knight, Nicholas Barnett, Reza Motallebzadeh, Gavin J Pettigrew   +31 more
doaj   +1 more source

Strength through diversity: how cancers thrive when clones cooperate

Molecular Oncology, EarlyView.
Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken, Maartje Witsen, Emile E. Voest, Krijn K. Dijkstra   +3 more
wiley   +1 more source